Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.

Drugs
Jörg Trojan

Abstract

Cabozantinib (Cabometyx®) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the "anexelekto" (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since November 2018) and in the USA (since January 2019). The approval of cabozantinib was based on results of the randomized, placebo-controlled, phase 3 CELESTIAL trial in patients with unresectable HCC, who received one or two prior lines of treatment including sorafenib. At the second planned interim analysis, the trial was stopped, because the primary end point overall survival was clearly in favor for cabozantinib. Additionally, median progression-free survival was superior to placebo. The most common ≥ grade 3 relevant adverse events in patients with HCC treated with cabozantinib were palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea. In this review, current data on cabozantinib for the treatment of patients with advanced HCC, with a focus on the management of common adverse events and ongoing clinical trials, are discussed.

References

May 23, 2002·American Journal of Physiology. Gastrointestinal and Liver Physiology·Dongfang WangMark L Welton
Feb 8, 2006·Annual Review of Physiology·Kenton M SandersSean M Ward
Jun 14, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E LacoutureJ Guitart
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Mar 23, 2010·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Sheng-Yu FanMing-Chih Ho
Dec 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip J JohnsonHidenori Toyoda
Apr 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R K KelleyE Van Cutsem
Sep 2, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mohamed BouattourSandrine Faivre
Oct 24, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Patrick SchöffskiGeoffrey I Shapiro
Nov 18, 2017·The Oncologist·Manuela Schmidinger, Romano Danesi
Apr 10, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Jul 5, 2018·The New England Journal of Medicine·Ghassan K Abou-AlfaRobin K Kelley
Jan 20, 2020·Journal of Hepatology·Sandrine FaivreRichard S Finn
Feb 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R MiksadG Abou-Alfa
May 14, 2020·The New England Journal of Medicine·Richard S FinnUNKNOWN IMbrave150 Investigators

❮ Previous
Next ❯

Citations

Mar 7, 2021·International Journal of Molecular Sciences·Mai-Huong Thi NgoYen-Hua Huang
Apr 4, 2021·International Journal of Molecular Sciences·Bingting YuMaikel P Peppelenbosch
Apr 7, 2021·Immunotherapy·Alessandro RizzoGiovanni Brandi
Apr 8, 2021·Journal of Hepatocellular Carcinoma·Antonio D'AlessioLorenza Rimassa

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03755791
NCT03170960
NCT01658878
NCT03539822
NCT03299946
NCT03963206
NCT04204850
NCT03586973

Software Mentioned

CELESTIAL
IMbrave150

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.